血液透析起始后痴呆、阿尔茨海默病与死亡风险
该研究基于美国肾脏数据系统与Medicare链接数据,纳入356,668例66岁及以上起始血液透析的ESKD患者,采用竞争风险模型估计痴呆和阿尔茨海默病的累积诊断风险,并分析相关因素及后续死亡风险。结果显示女性1年和5年痴呆诊断风险分别为4.6%和16%,男性为3.7%和13%;诊断痴呆或阿尔茨海默病后死亡风险约增加两倍。
要点
- 老年血液透析患者痴呆1年风险女性4.6%、男性3.7%,5年风险女性16%、男性13%。
- 年龄≥86岁、黑人种族、女性及机构化是痴呆和阿尔茨海默病诊断的独立危险因素。
- 透析患者诊断痴呆后死亡风险增加2.14倍,诊断阿尔茨海默病后增加2.01倍。
核心结论
- 老年血液透析患者痴呆和阿尔茨海默病诊断风险高,且诊断后死亡风险约增加两倍。
研究设计与样本
- 基于美国肾脏数据系统与Medicare链接数据的回顾性队列研究,纳入356,668例年龄≥66岁、2001年1月1日至2013年12月31日期间起始血液透析的ESKD患者。
- 采用竞争风险模型(考虑死亡、透析方式变更和肾移植)估计痴呆和阿尔茨海默病的累积诊断风险,采用Cox比例风险模型估计后续死亡风险。
主要发现
- 女性1年和5年痴呆诊断风险分别为4.6%和16%,男性分别为3.7%和13%。
- 女性1年和5年阿尔茨海默病诊断风险分别为0.6%和2.6%,男性分别为0.4%和2.0%。
- 痴呆诊断的最强独立危险因素包括年龄≥86岁(HR 2.11,95%CI 2.04-2.18)、黑人种族(HR 1.70,95%CI 1.67-1.73)、女性(HR 1.10,95%CI 1.08-1.12)和机构化(HR 1.36,95%CI 1.33-1.39)。
- 阿尔茨海默病诊断的最强独立危险因素包括年龄≥86岁(HR 2.11,95%CI 1.97-2.25)、黑人种族(HR 1.78,95%CI 1.71-1.85)、女性(HR 1.12,95%CI 1.08-1.16)和机构化(HR 1.10,95%CI 1.05-1.15)。
- 诊断痴呆后后续死亡风险增加2.14倍(95%CI 2.07-2.22),诊断阿尔茨海默病后增加2.01倍(95%CI 1.89-2.15)。
临床怎么用
- 对老年血液透析患者应关注认知功能变化,尤其高龄、黑人、女性及机构化患者。
- 痴呆或阿尔茨海默病诊断可作为死亡风险分层的重要参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Older patients with ESKD experience rapid declines in executive function after initiating hemodialysis; these impairments might lead to high rates of dementia and Alzheimer's disease in this population. We estimated incidence, risk factors, and sequelae of diagnosis with dementia and Alzheimer's disease among older patients with ESKD initiating hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied 356,668 older (age ≥66 years old) patients on hemodialysis (January 1, 2001 to December 31, 2013) from national registry data (US Renal Data System) linked to Medicare. We estimated the risk (cumulative incidence) of diagnosis of dementia and Alzheimer's disease and studied factors associated with these disorders using competing risks models to account for death, change in dialysis modality, and kidney transplant. We estimated the risk of subsequent mortality using Cox proportional hazards models. RESULTS: The 1- and 5-year risks of diagnosed dementia accounting for competing risks were 4.6% and 16% for women, respectively, and 3.7% and 13% for men, respectively. The corresponding Alzheimer's disease diagnosis risks were 0.6% and 2.6% for women, respectively, and 0.4% and 2.0% for men, respectively. The strongest independent risk factors for diagnosis of dementia and Alzheimer's disease were age ≥86 years old (dementia: hazard ratio, 2.11; 95% confidence interval, 2.04 to 2.18; Alzheimer's disease: hazard ratio, 2.11; 95% confidence interval, 1.97 to 2.25), black race (dementia: hazard ratio, 1.70; 95% confidence interval, 1.67 to 1.73; Alzheimer's disease: hazard ratio, 1.78; 95% confidence interval, 1.71 to 1.85), women (dementia: hazard ratio, 1.10; 95% confidence interval, 1.08 to 1.12; Alzheimer's disease: hazard ratio, 1.12; 95% confidence interval, 1.08 to 1.16), and institutionalization (dementia: hazard ratio, 1.36; 95% confidence interval, 1.33 to 1.39; Alzheimer's disease: hazard ratio, 1.10; 95% confidence interval, 1.05 to 1.15). Older patients on hemodialysis with a diagnosis of dementia were at 2.14-fold (95% confidence interval, 2.07 to 2.22) higher risk of subsequent mortality; those with a diagnosis of Alzheimer's disease were at 2.01-fold (95% confidence interval, 1.89 to 2.15) higher mortality risk. CONCLUSIONS: Older patients on hemodialysis are at substantial risk of diagnosis with dementia and Alzheimer's disease, and carrying these diagnoses is associated with a twofold higher mortality.
引用
- McAdams-DeMarco MA, Daubresse M, Bae S, et al. Dementia, Alzheimer's Disease, and Mortality after Hemodialysis Initiation. Clin J Am Soc Nephrol. 2018. PMID: 30093374. doi:10.2215/CJN.10150917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。